History of Medicine


An Open Access Journal

Effects pf Biological Response Modifiers on the Prevalence pf Autoantibodies to Vascular Injury in Agroup of Iraqi Patients with Autoimmune Disease

Jamal Nasser Farhood
Collage of biotechnology, Al-Qādisiyyah university, Iraq


Background; .biological disease modifiers mainly those targeting tumor necrosis factor (Etanercept), (Infliximab), together with (Adalimumab) are currently an important part of the treatment plan for seropositive poly-articular arthropathy. Since these drugs greatly affect the course of the disease, they alter the treatment of this condition and significantly slow down X-ray progression of the aforementioned condition. Some biologics are designed to precisely suppress tumor necrosis factor (TNF), a key regulator of joint pain and damage. Tumor necrosis factor is a predominant inflammatory interleukin which synchronizes the release of other soluble mediators [1]. Purpose: to assess the changes in P-ANCA an indicator of vascular injury after treatment with the biologic Etanercept (anti-TNFα) in patients with refractory seropositive polyarticular arthropathy. Methods: patients with refractory and classically unrelieved seropositive poly-articular arthropathy received a biological modulator (Etanercept) for 3 months. Participants' sera were collected and examined consecutively for P-ANCA at baseline as well as post-dosing. Statistical analysis was performed using the SPSS 10 .Results: after 3 months, there was a significant decrease in serum anti-lactoferrin level of nearly 97%, and a concomitant increase of anti-lysozyme, with an increase of 551.6%. However, other autoantibodies are elevated, non-importantly.  Conclusion: Etanercept had variable effects on P-ANCA in patients with refractory seropositive poly arthropathy after 3 months of therapy.

Keywords: autoantibodies, vascular injury, Iraqi patients , autoimmune disease ,


From 2021

The Journal is Published Twice a Year.

Founders of the journal

I.M. Sechenov

For Authors